Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
February 14, 2017 8:47 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Outperform rating and $42 price target on Teva Pharmaceuticals Industries (NYSE: TEVA), suggesting strategic questions remain, despite the company reporting 2016 fourth quarter results above consensus.
Stanicky comments, "TEVA reported 4Q above Street expectations and reaffirmed 2017... More
Teva Pharma (TEVA) Weighing Options for Branded Generics Unit to Cut Debt - Bloomberg
February 13, 2017 11:35 AM EST(Updated - February 13, 2017 11:41 AM EST)
Teva Pharma (NYSE: TEVA) is weighing options for its branded generics unit in an effort to reduce debt, Bloomberg reported citing people familiar with the mater.
The unit could be valued at several billion dollars, and... More
Teva Pharma (TEVA) volatility comes in after solid Q4 and outlook
February 13, 2017 11:26 AM ESTTeva Pharma (NYSE: TEVA) February call option implied volatility is at 38 compared to a level of 56 from last week, March is at 31; compared to its 52-week range of 19 to 50 after solid Q4 and outlook.
... MoreTeva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
February 13, 2017 6:43 AM EST(Updated - February 13, 2017 6:44 AM EST)
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.38, $0.02 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.26 billion.
Teva reaffirms its 2017 full year non-GAAP guidance; including revenues of $23.8 - 24.5 billion, and non-GAAP EPS of $4.90 - 5.30
"2016 was a transitional year for Teva - one that... More
